Cleerly

Cleerly's mission is to eliminate heart attacks by creating a new global standard of precision heart care. The company leverages artificial intelligence trained on millions of images from over 40,000 patients to provide physicians with detailed, quantitative, and actionable insights into coronary artery disease from standard CCTA scans. Its platform is supported by a robust body of clinical evidence from major trials like CREDENCE and PACIFIC, demonstrating high diagnostic accuracy for ischemia and prognostic value for major adverse cardiac events (MACE). Cleerly is focused on driving adoption among healthcare providers, payors, and patients to transform cardiac risk assessment.

An AI-driven, cloud-based software platform that performs a comprehensive, quantitative analysis of coronary CT angiography (CCTA) scans to measure plaque, evaluate stenosis, and predict ischemia, enabling personalized heart attack risk assessment.

Total raised: $235M

Cleerly's main competitors include HeartFlow (FFR~CT~) and traditional non-invasive stress tests (SPECT, PET). Its differentiation lies in providing comprehensive plaque quantification and characterization beyond just ischemia prediction, backed by strong clinical trial data showing diagnostic accuracy and prognostic value for future cardiac events.